IBD medicines guidance by MedicijnWijs

Pharmi is honored that many pharmacists want to conduct research with MedicijnWijs.
An example within the IBD indication from the Máxima MC in Eindhoven.

Patients with an inflammatory bowel disease (IBD) almost always require chronic medication, with approximately 50% of children and only 25 to 35% of adolescents known to have adequate adherence to therapy.

Good compliance is necessary in IBD to reduce disease activity and prolong periods of remission.
Understanding of the medication and disease and interactive digital guidance can have a positive effect on therapy compliance.

The aim of the study was to investigate the effect of MedicijnWijs on compliance with the use of azathioprine in IBD patients aged 12 to 17 years. The effect on knowledge about IBD and the ease of use of MedicijnWijs was also examined.

A multicenter “before-after” study design was chosen, with 2 other centers planned to participate.
Positive trends were observed in improving adherence to azathioprine and knowledge of IBD. The use of MedicijnWijs was also experienced as easy.

At present, no further firm conclusions can be drawn from the study, as the study population was small and results were not statistically significant.
In the remainder of the study, the potential of MedicijnWijs will therefore be further investigated in a larger multi-center setting.

Many thanks to the team of the Máxima MC for the first great step in this research: Kaylee Stabèl, Coby Mesman, Imke Bertrams-Maartens and Luc Derijks.
More information about this and other research with MedicijnWijs can be requested via zorg@pharmi.info